Testing effectiveness (Phase 2)Active Not RecruitingNCT03317158
What this trial is testing
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Who this might be right for
Urothelial CarcinomaBladder Cancer
Noah Hahn, M.D. 186